METRO is moving toward the purchase of only zero-emission buses by 2030. Image courtesy of NovaBus

Within the next year or so, you’ll see electric-powered buses buzzing around Bayou City.

The Metropolitan Transit Authority of Harris County (METRO) recently awarded a $22 million contract to Saint-Eustache, Canada-based Nova Bus for the production of 20 battery-powered electric buses. The contract includes an option for another 20 buses.

The first 20 buses, to be manufactured at the Nova Bus factory in Plattsburgh, New York, are expected to be on local roads sometime in in late 2022 or early 2023. They’ll run on the 402 Bellaire Express (Quickline) and 28 OST-Wayside routes.

METRO also plans to test three to five electric buses powered by hydrogen fuel cells. Furthermore, METRO is a member of the Automated Bus Consortium, a national organization of transportation agencies working toward development of a full-size, electric-powered automated bus.

METRO is moving toward the purchase of only zero-emission buses by 2030. It eventually wants to operate more than 1,200 electric buses throughout its system. All types of buses account for 1 percent of transportation-caused greenhouse gases in Houston, according to METRO.

Nova Bus, owned by Swedish automaker Volvo, says its electric vehicles reduce greenhouse gas emissions while also cutting maintenance costs.

“METRO is paying close attention to the climate assessments showing Houston will grapple with rising temperatures and more frequent weather events. It is more critical than ever that METRO map out a plan to not only prepare for these events but to mitigate the impact they have on our community as much as we can,” Carrin Patman, chairwoman of the METRO board, says in a recent presentation.

President Biden has tapped Patman, a Houston attorney, to be the U.S. ambassador to Iceland.

Patman has appointed METRO board members Chris Hollins, former Harris County clerk, and Terry Morales, an executive at Amegy Bank, to shepherd the agency’s efforts to combat climate change.

“The impact of climate change is a significant threat to the health and safety of our community,” Hollins says in the METRO presentation. “METRO can and will be a leader in helping the region respond to this challenge.”

“Beginning with the deployment of clean fleet technology,” he adds, “METRO will lead the way in green transit. METRO is taking a holistic approach — transforming not just our buses, but all our business practices — to increase sustainability, resiliency, and carbon emissions reduction.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”